Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information (Tables)

12 Months Ended

Jun. 30, 2022

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

Changes in accumulated other comprehensive income (loss) attributable to Bio-Techne, net of tax, are summarized as follows (in thousands):


	Unrealized
	Gains		Foreign
	(Losses) on		Currency
	Derivative		Translation
	Instruments		Adjustments		Total
Balance June 30, 2019	$	(9,537)	$	(73,983)	$	(83,521)
Other comprehensive income (loss) before reclassifications		(7,179)		(9,963)		(17,142)
Reclassification from loss on derivatives to interest expense, net of taxes⁽¹⁾		3,464		—		3,464
Balance June 30, 2020⁽³⁾	$	(13,253)	$	(83,946)	$	(97,199)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne⁽²⁾		100		32,848		32,948
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne⁽¹⁾		6,960		—		6,960
Balance as of June 30, 2021⁽³⁾	$	(6,193)	$	(51,098)	$	(57,291)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne⁽²⁾		9,403		(32,171)		(22,768)
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne⁽¹⁾		4,859				4,859
Balance as of June 30, 2022⁽³⁾	$	8,069	$	(83,269)	$	(75,200)

(1)

Gains (losses) on the interest swap will be reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified $6,352 to interest expense and recorded a related tax benefit of $1,493 during fiscal 2022. The Company reclassified $8,598 to interest expense and $512 to non-operating income relating to variable interest payments that were probable not to occur for the fiscal year ended June 30, 2021. The Company also recorded a related tax benefit of $2,150 during fiscal 2021. The Company reclassified $4,503 to interest expense and a related tax benefit tax of $1,040 during fiscal 2020.

(2)	Other comprehensive income related to foreign currency translation adjustments in the table above includes the amount attributable to Bio-Techne and excludes the $70 and $103 attributable to the non-controlling interest in Eminence as of June 30, 2022, and June 30, 2021, respectively.

(3)	The Company had a net deferred tax liability of $2,480 as of June 30, 2022, and net deferred tax benefits of $1,908 and $4,058 as of June 30, 2021, and June 30, 2020, respectively.